

# ForPatients

by Roche

Stroke

## A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke

**Trial Status**  
Terminated

**Trial Runs In**  
2 Countries

**Trial Identifier**  
NCT02928393 2015-003227-66  
BP29937

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This Phase IIa, randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety, efficacy and pharmacodynamics of basmisanil in adult participants with severe motor impairment following an ischemic stroke.

**Hoffmann-La Roche**  
Sponsor

**Phase 2**  
Phase

---

**NCT02928393 2015-003227-66 BP29937**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
All

**Age**  
>=40 Years & <= 85 Years

**Healthy Volunteers**  
No

---